Marketing-authorisation holder · Canada
Celltrion Inc.
36 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
36 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 36
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AVTOZMA162 mg / 0.9 ml · Solution | Tocilizumab | Canada | Marketed | 2026 |
| AVTOZMA200 mg / 10 ml · Solution | Tocilizumab | Canada | Marketed | 2026 |
| AVTOZMA80 mg / 4 ml · Solution | Tocilizumab | Canada | Marketed | 2026 |
| AVTOZMA400 mg / 20 ml · Solution | Tocilizumab | Canada | Marketed | 2026 |
| AVTOZMA162 mg / 0.9 ml · Solution | Tocilizumab | Canada | Marketed | 2026 |
| EYDENZELT2 mg / 0.05 ml · Solution | Aflibercept | Canada | Marketed | 2026 |
| EYDENZELT2 mg / 0.05 ml · Solution | Aflibercept | Canada | Marketed | 2026 |
| HERZUMA150 mg / vial · Powder For Solution | Trastuzumab | Canada | Marketed | 2021 |
| HERZUMA440 mg / vial · Kit, Powder For Solution | Trastuzumab | Canada | Marketed | 2019 |
| OMLYCLO75 mg / 0.5 ml · Solution | Omalizumab | Canada | Marketed | 2026 |
| OMLYCLO300 mg / 2 ml · Solution | Omalizumab | Canada | Authorised | |
| OMLYCLO150 mg / 1 ml · Solution | Omalizumab | Canada | Marketed | 2025 |
| OMLYCLO150 mg / 1 ml · Solution | Omalizumab | Canada | Marketed | 2026 |
| OMLYCLO75 mg / 0.5 ml · Solution | Omalizumab | Canada | Marketed | 2025 |
| OMLYCLO300 mg / 2 ml · Solution | Omalizumab | Canada | Authorised | |
| OSENVELT120 mg / 1.7 ml · Solution | Denosumab | Canada | Marketed | 2025 |
| REMDANTRY100 mg / vial · Powder For Solution | Infliximab | Canada | Marketed | 2014 |
| REMSIMA SC120 mg / ml · Kit, Solution | Infliximab | Canada | Marketed | 2021 |
| REMSIMA SC120 mg / ml · Kit, Solution | Infliximab | Canada | Authorised | |
| STEQEYMA45 mg / 0.5 ml · Solution | Ustekinumab | Canada | Authorised | |
| STEQEYMA90 mg / 1 ml · Solution | Ustekinumab | Canada | Marketed | 2026 |
| STEQEYMA45 mg / 0.5 ml · Solution | Ustekinumab | Canada | Marketed | 2024 |
| STEQEYMA45 mg / 0.5 ml · Solution | Ustekinumab | Canada | Authorised | |
| STEQEYMA90 mg / 1 ml · Solution | Ustekinumab | Canada | Marketed | 2024 |
| STEQEYMA IV5 mg / ml · Solution | Ustekinumab | Canada | Marketed | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 36 | 35 | 1 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.